SolaranRx, Inc. is developing a new class of precision medicine: therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics, often referred to as theranostics, constitutes a new level of precision medicine for treating metastatic melanoma.